Trials / Terminated
TerminatedNCT01541670
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of Anti-MIF Antibody in subjects with lupus nephritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody | Intravenous injection |
Timeline
- Start date
- 2011-11-28
- Primary completion
- 2012-12-31
- Completion
- 2012-12-31
- First posted
- 2012-03-01
- Last updated
- 2021-05-05
Locations
24 sites across 5 countries: United States, Australia, Canada, Mexico, New Zealand
Source: ClinicalTrials.gov record NCT01541670. Inclusion in this directory is not an endorsement.